+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years - 80Years
All Genders
ID07071103

Study of Intestinal Low-Dose Radiotherapy Combined with PD-1PD-L1 Immunotherapy for Adults with Metastatic Solid Tumors Resistant to Previous Immunotherapy

Led by Chuangzhen Chen · Updated on 2025-11-20

48

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the combination of intestinal low-dose radiotherapy ILDR with PD-1PD-L1 monoclonal antibody therapy in patients who have metastatic solid tumors that have become resistant to prior immune checkpoint blockade ICB treatments. This phase II clinical trial aims to understand the clinical benefit and safety of this combined approach across three groups based on tumor type lung cancer, esophageal cancer, and other solid tumors. The study is motivated by evidence suggesting ILDR may enhance immune responses by affecting the gut environment, potentially improving immunotherapy effectiveness. All participants receive a single 1 Gy dose of radiotherapy targeting the jejunum and ileum, followed within 24 hours by PD-1PD-L1 antibody treatment administered every three weeks. Patients continue maintenance therapy for up to two years. The trial includes three parallel cohorts with 16 patients each, focusing on different tumor types, and assesses treatment responses and safety based on established criteria. Tissue, stool, and blood samples are collected before and after treatment for advanced analyses to explore how the gut microbiota and immune system interact. Participants undergo regular evaluations including scans to measure tumor response, assessments of side effects, and immune and microbiota studies at multiple time points up to 48 weeks. Primary outcomes include objective and disease control response rates, progression-free survival, and observation of abscopal effects at 6, 12, and 24 weeks. Secondary outcomes focus on overall survival, cancer-specific survival, and adverse events. This comprehensive monitoring aims to clarify how ILDR influences immunotherapy resistance and identify markers linked to treatment outcomes.

CONDITIONS

Brief Title

Intestinal Low Dose Radiotherapy Combined With Immunotherapy in Immune-resistant Metastatic Malignant Solid Tumors

Research Team

C

Chuangzhen Chen, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here